GeoVax CEO to Present at Healthcare Investment Conference, Highlighting Vaccine Pipeline Progress

GeoVax Labs, Inc. announced that Chairman and CEO David Dodd will participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Yale Club in New York City. The conference serves as an invite-only event connecting healthcare companies with institutional investors through 1-on-1 meetings and panel discussions. This format provides extensive opportunities for executive management teams to deliver in-depth insights into company strategies, pipelines, and upcoming milestones to ROTH's institutional clients.

During the conference, Dodd will be available to meet with investors and discuss GeoVax's pipeline progress across multiple vaccine platforms. The company's GEO-MVA, an MVA-based Mpox/smallpox vaccine positioned to support global preparedness and stockpile strategies, recently received favorable Scientific Advice from the European Medicines Agency. This regulatory guidance suggests the vaccine candidate may progress directly to Phase 3 clinical evaluation, potentially accelerating its development timeline by omitting earlier phase trials.

GeoVax's COVID-19 vaccine candidate, GEO-CM04S1, represents another significant component of the company's pipeline currently being evaluated in three Phase 2 clinical trials across various patient populations. The multi-antigen vaccine is being studied as a primary vaccine for immunocompromised patients, including those with hematologic cancers, where current authorized COVID-19 vaccines have demonstrated limitations. Additional trials are examining GEO-CM04S1 as a booster vaccine in patients with chronic lymphocytic leukemia and as a more robust, durable COVID-19 booster among healthy patients who previously received mRNA vaccines.

In the oncology space, GeoVax is advancing Gedeptin®, a gene-directed enzyme prodrug therapy for solid tumors, with a planned Phase 2 trial focusing on head and neck cancer. The company recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers, building on its immuno-oncology platform. GeoVax maintains a strong intellectual property portfolio supporting its technologies and product candidates, holding worldwide rights for its innovations.

The participation in the ROTH Healthcare Opportunities Conference comes at a strategic time for GeoVax as the company advances multiple clinical programs through key development stages. The conference format allows for detailed discussions about the company's progress across both infectious disease vaccines and cancer therapies, providing investors with comprehensive updates on clinical milestones and regulatory developments. For more information about the company's clinical trials and technology platform, visit https://www.geovax.com.